Antiviral treatment of COVID-19: which role can clinical parameters play in therapy evaluation?
Infection
.
2023 Dec;51(6):1855-1861.
doi: 10.1007/s15010-023-02081-0.
Epub 2023 Aug 9.
Authors
Yannis R Hübner
1
,
Nikolai Spuck
2
,
Moritz Berger
2
,
Stefan Schlabe
1
3
,
Gereon J Rieke
1
3
,
Sven Breitschwerdt
1
3
,
Kathrin van Bremen
1
3
,
Christian P Strassburg
1
,
Maria A Gonzalez-Carmona
1
,
Jan-Christian Wasmuth
1
3
,
Jürgen K Rockstroh
1
3
,
Christoph Boesecke
1
3
,
Malte B Monin
4
5
Affiliations
1
Department of Internal Medicine I, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
2
Faculty of Medicine, Institute of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany.
3
German Centre for Infection Research (DZIF), partner-site Cologne-Bonn, Bonn, Germany.
4
Department of Internal Medicine I, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. malte_benedikt.monin@ukbonn.de.
5
German Centre for Infection Research (DZIF), partner-site Cologne-Bonn, Bonn, Germany. malte_benedikt.monin@ukbonn.de.
PMID:
37555885
PMCID:
PMC10665228
DOI:
10.1007/s15010-023-02081-0
No abstract available
Publication types
Letter
MeSH terms
Antiviral Agents / therapeutic use
COVID-19*
Humans
SARS-CoV-2
Substances
Antiviral Agents